Lv22
186 积分 2025-06-17 加入
The Paradox and Future of GLP-1/GIP Combination Therapies: Efficacy and Mechanisms
5天前
已完结
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis
13天前
已关闭
MASLD/MASH and type 2 diabetes: Two sides of the same coin? From single PPAR to pan-PPAR agonists
20天前
已完结
The landscape of small-molecule prodrugs
1个月前
已完结
Opportunities and challenges of targeting cGAS–STING in cancer
2个月前
已完结
Opportunities and challenges of targeting cGAS–STING in cancer
2个月前
已完结
Efimosfermin alfa (BOS-580) once per month in people with metabolic dysfunction-associated steatohepatitis with F2 or F3 fibrosis: results from a 24-week, randomised, double-blind, placebo-controlled, phase 2 trial
3个月前
已完结
A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis
3个月前
已完结
Lessons from incretin-based therapy in MASH and obesity
3个月前
已完结
Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis
3个月前
已完结
Antimicrobial activity of zinc oxide (ZnO) nanoparticle againstKlebsiella pneumoniae
马来酸曲美布汀联合匹维溴铵治疗腹泻型肠易激综合征临床疗效评价
皖公网安备34019202002308
